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Abstract 
Purpose: To study the effectiveness of various nonsteroidal anti-inflammatory drugs (NSAIDs) in 
patients with vertebral fractures.  
Methods: A total of 78 patients (17 males and 61 females) with a mean age of 69.5 years were 
included. The major inclusion criterion was an osteoporotic vertebral fracture between T7 and L3. The 
exclusion criteria included fractures above T7 and below L3; and other bone disorders such as disc 
herniation, spondylolisthesis, an infection, or a tumour. Pain intensity was assessed with the aid of a 10-
point visual analogue scale (VAS). Bone mineral density (BMD) data, delay in reunion, and any other 
matter of significance, were discussed with the treating doctors and cross-checked with independent 
doctors. The NSAIDs given were non-selective cyclo-oxygenase (COX) inhibitors (naproxen, 
indomethacin and flurbiprofen) and selective COX 2 inhibitors (piroxicam, celecoxib, and rofecoxib). All 
data were compiled and appropriately analysed.  
Results: Some NSAIDs interfered with bone healing. No male required surgery, but two females taking 
naproxen, one taking flurbiprofen, and another taking celecoxib, required surgery. In terms of bone 
healing, non-union and delay in reunion were more evident in those taking naproxen, indomethacin or 
flurbiprofen than in those taking piroxicam, celecoxib, or rofecoxib. All T scores were lower than -2.5, 
indicating that all the patients were osteoporotic. Positive changes in T scores after 12 weeks were 
evident only in those taking rofecoxib, celecoxib, or piroxicam. VAS scores were also better in these 
patients.  
Conclusions: Celecoxib seems to be the best of the six NSAIDs in terms of both analgesia and bone 
health. The study recommends the use of celecoxib in patients with vertebral fractures. 
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Nonsteroidal anti-inflammatory drugs (NSAIDs) 
are prescribed very frequently to patients with 
lumbar or intervertebral disc disorders for the 
effective management of pain and inflammation 
[1,2]. Chronic use of NSAIDs often causes one or 
more side-effects including gastric irritation, 
stomach ulcers, gastrointestinal bleeding, renal 
failure, cardiac arrest, and stroke [3-6]. Relief 
from the severe pain associated with lumbar 
disorders requires high doses of NSAIDs for 
prolonged periods of time. NSAIDs inhibit cyclo-
oxygenase (COX) enzymes. COX-1 is involved in 
physiological functions including haemostasis 
and gastric protection. COX-2(which is inducible) 
mediates pain, inflammation, and fever, in turn 
inhibiting the synthesis of prostaglandins from 
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arachidonic acid. NSAIDs affect bone destruction 
and bone formation by the pathway mediated by 
COX-2 only [7,8]. 
 
Decades-long investigations have explored the 
roles played by NSAIDs in bone healing, pain, 
and management of inflammation. Several 
studies have suggested that NSAIDs interfere 
with bone healing; many other studies instead 
found NSAIDs to be safe and effective. Effective 
analgesia is not an issue, but safety profiles have 
always been of concern [9,10]. Older patients 
often have bone diseases such as osteoporosis 
which is a systemic skeletal disease 
characterised by reductions in bone mass and 
bone tissue. The bones become fragile and 
prone to fracture. Bone mineral density (BMD) is 
reduced in osteoporotic patients. Osteoporosis is 
very common in post- menopausal women, 
caused principally by oestrogen deficiency. The 
bones (particularly the femora, vertebrae, and 
radii) become fragile and porous. Aging and 
androgen deficiency cause osteoporosis in 
males. Treatment seeks to reduce bone 
resorption and increase bone formation, either by 
inhibiting osteoclasts and/or stimulating 
osteoblasts [11,12].Vertebral fractures are the 
most common fractures in osteoporotic patients. 
In the present work, we studied the effectiveness 







The study was performed in the Department of 
Orthopaedics, Jining No.2 People’s Hospital, 
Jining City, from January 2014 to December 
2015. Patient data were collected from hospital 




The study was carried out in accordance with the 
guidelines of the Declaration of Helsinki of 1975 
[13], and received the prior approval of the 
institutional Review Board of Jining No. 2 
People’s Hospital, Jining City (approval no.  
JPH/ortho/2014/12-e02; 04/12/14). Prior consent 
was given by each patient and the hospital 
administration for sharing of (anonymous) 
medical records. Patients were divided into six 
groups depending on the type of NSAID 
administered (Table 1). 
 
A total of 78 patients (17 males and 61 females) 
with an average age of 69.5 years were included. 
The major inclusion criterion was an osteoporotic 
vertebral fracture between T7 and L3. The 
exclusion criteria included fractures above T7 
and below L3; and other bone disorders such as 
disc herniation, spondylolisthesis, infection, or 
tumour. Pain intensity was assessed by a 10-
point visual analogue scale (VAS). The BMD 
data, any delay in reunion, and any other matter 
of significance, were discussed with the treating 
doctors and cross-checked with independent 
doctors. 
 
Patients were given different NSAIDs. The non-
selective COX inhibitors were naproxen, 
indomethacin, and flurbiprofen; the selective 
COX 2 inhibitors were piroxicam, celecoxib, and 
rofecoxib. Patients were blinded to their drugs 
until study completion at 12 weeks. 
 
From 6 weeks onward, the effects of NSAIDs on 
bone health were evaluated on the basis of any 
need for surgery, bone non-union, and any delay 
in reunion. All parameters were evaluated on a 
BMD basis (derived using dual energy X-ray 
absorptiometry [DXA]); we calculated T-scores 
for all patients. Routine check-ups covered other 
qualitative factors; these were evaluated by all 
three independent experts in terms of final 
outcomes. 
 
Clinical analgesic performance: Pain score 
study 
 
VAS pain scores in 78 subjects were recorded 
weekly. Pain was assessed prior to treatment 
(baseline), and weekly up to 6 weeks after 
treatment, using a 10-cm VAS (ranging from 0 
[no pain] to 10 [worst pain imaginable]). All 
patients were taking NSAIDs regularly. 
 
     Table 1: Study groups and treatment applied 
 
Group code NSAID Dose (p.o.) Number of patients (male/female) 
N Naproxen  250 mg qid 13 (2/11) 
I Indomethacin 25 mg qid 14 (3/13) 
F Flurbiprofen 50 mg tid/ qid 11 (1/10) 
P Piroxicam 20 mg OD for 4 weeks 13 (3/ 10) 
C Celecoxib 200 mg bd 12 (3/9) 
R Rofecoxib 25 mg od 15 (5/ 10) 
      NSAID = non-steroidal anti-inflammatory drug 
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All data are expressed as mean ± standard 
deviation. Statistical analysis featured two-way 
analysis of variance (ANOVA) performed using 
SPSS for Windows software (SPSS Inc, 





VAS pain scores were recorded weekly. BMDs 
were derived in weeks 1 and 12. Any delay in 
reunion, non-union, or surgical requirement was 
assessed by three independent experts. 
Table 2 compares the effectiveness of various 
NSAIDs in patients with vertebral fractures. We 
observed that some NSAIDs interfered with bone 
healing. No male required bone surgery, but two 
females taking naproxen, one taking flurbiprofen, 
and one taking celecoxib, required surgery 
(Table 2). 
 
In terms of bone healing, non-union and delay in 
reunion were more common in those taking 
naproxen, indomethacin, or flurbiprofen than in 
those taking piroxicam, celecoxib, or rofecoxib 
(Figure 1 and Figure 2). 
 
 
Table 2: Effect of NSAIDs on various parameters of bone health 
 











Naproxen  2 (0/2) 6 (1/5) 7 (2/5) -2.67 -2.70 
Indomethacin 0 3 (1/2) 4 (0/4) -2.60 -2.64 
Flurbiprofen 1  (0/1) 5  (1/4) 4 (1/3) -2.59 -2.70 
Piroxicam,  0 5 (1/4) 3 (1/2) -2.70 -2.68 
Celecoxib 1 (0/1) 2 (0,2) 1 (0/1) -2.66 -2.45 
Rofecoxib 0 1 (0,1) 2 (0/2) -2.57 -2.50 
NSAID = non-steroidal anti-inflammatory drug 
 
 
Figure 1: Non-union of bones observed in patients 




Figure 2: Delay in reunion of bones observed in 
patients receiving different NSAIDs 
 
T-scores were used to assess bone health. Bone 
healing was evaluated using DXA. The T-scores 
were all lower than -2.5, indicating that all 
patients were osteoporotic. The T-scores 
improved after 12 weeks only in those taking 
rofecoxib, celecoxib, and piroxicam (Table 2). 
 
VAS pain scores were also lower in those taking 




Patients were asked to give pain scores (from 0 
{no pain} to 10 {worst pain imaginable}). VAS 
scores have been studied in postoperative 
patients suffering from strong pain (scores of ≥ 9) 
[14]. The VAS is quite reliable, showing high test 
and retest repeatability; it is also very sensitive 
and can measure multiple dimensions of pain. 
 
The T-score is a parameter derived from BMD; 
the BMD of a subject is compared to that of a 
healthy 30-year-old: ideally, the score should be 
zero. According to National Institutes of Health 
(NIH) guidelines, a score from 1 to -1 indicates a 
normal BMD; as core from -1 to -2.5indicates low 
bone mass and a score of -2.5 or lower indicates 
severe osteoporosis with bone fractures [15]. 
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Naproxen  Indomethacin  Flurbiprofen Piroxicam Celecoxib Rofecoxib 
0 9.90±0.02 9.99±0.20 8.87±0.01 9.90±0.10 9.90±0.01 9.80±0.01 
1 8.01±0.20 9.01±0.07 7.69±1.01 8.01±0.10 8.98±0.01 8.60±0.40 
2 7.50±0.12 8.80±0.40 5.86±0.22 7.87±0.04 6.90±0.32 7.06±0.54 
4 7.00±0.25 7.96±0.24 4.96±1.20 7.01±0.41 6.02±0.04 6.06±0.60 
6 6.00±0.10 7.20±0.25 6.01±0.02 6.01±1.04 5.69±0.25 4.26±1.42 
8 6.75±0.15 6.50±1.15 5.22±1.20 4.22±1.01 4.90±1.02 3.02±1.22 
12 5.50±1.02 5.00±1.20 4.58±1.50 4.20±1.02 2.89±1.02 2.20±1.62 
All study data were derived from racially homogenous patients. 
 
One large study concluded that patients treated 
with celecoxib (200 to 800 mg/day) enjoyed 
better outcomes than those treated with 
nonselective NSAIDs such as diclofenac, 
ibuprofen, naproxen, ketoprofen, and loxoprofen 
[16]. We also found that the selective COX2 
inhibitors afforded the best analgesia [17]. 
 
We found that the various NSAIDS affected bone 
health differently. Although COX2 inhibitors are 
safer, their possible effects on delay in bone 
reunion and non-union required study. Various 
reports on drug dose-dependent effects on bone 
health have appeared, although in the present 
study, we did not administer different doses of 
NSAIDs [18-20]. The COX-selectivity of an 
NSAID governs the efficacy of analgesia as well 
as bone health. 
 
Limitations of the study 
 
Response to drugs may vary with age; we did not 
consider the age effect. Moreover, pain 
perception may differ slightly from subject to 
subject. A study including a larger number of 
subjects with similar kinds of fracture would yield 




NSAIDs that selectively inhibit COX2 enzyme 
effectively alleviate pain but their effects on bone 
health required analysis. In general, prolonged 
use of non-selective inhibitors is no safer than 
selective inhibitors for patients with vertebral 
fractures. However, further dose and time studies 
are required. We found that celecoxib was the 
best of the six NSAIDs, both in terms of 
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